Drug Profile
Research programme: alpha-galactosylceramide - Kotobuki Pharmaceutical
Alternative Names: Alpha GalCer; KT7-533; α GalCer; α-C-galactosylceramideLatest Information Update: 24 Jul 2023
Price :
$50
*
At a glance
- Originator Kotobuki Pharmaceutical
- Class Adjuvants; Antineoplastics; Galactosylceramides; Small molecules
- Mechanism of Action Immunostimulants; Natural killer T cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 24 Jul 2023 alpha-galactosylceramide is still in preclinical trials for cancer in Japan (Kotobuki's Pharma pipeline, July 2023)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in Japan
- 24 Feb 2015 Alpha-galactosylceramide is available for licensing as of 24 Feb 2015. www.kotobuki-pharm.co.jp